Search results
Showing 8116 to 8130 of 8216 results
Recruitment begins to fill up to seven non-executive roles on the NICE board
Roles will contribute to the development of NICE’s strategic objectives
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term and is now enshrined in NICE guidance.
The Health Technology Assessment International (HTAi) 2021 Annual Meeting will be held virtually from 19-23 June 2021, and registration is now open.
Rehabilitation after traumatic injury should support people in resuming their lives
NICE has today (27 July 2021) published a new draft guideline covering rehabilitation after traumatic injury.
Remove earwax if a build-up is causing hearing loss problems, NICE tells primary care
GP surgeries or community clinics should offer to remove earwax if a build-up is contributing to someone’s hearing loss.
NICE launches The Office for Market Access to work with industry to speed up the adoption of new medicines, devices and diagnostics by the NHS.
The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access has been recommended for routine use in the NHS by NICE in final draft guidance published today (24 February).
One-stop-shop for AI and digital regulations for health and social care launched
New online advice service launched to help the NHS and wider care system adopt and make use of new digital and artificial intelligence
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund
More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund.
New potentially life-extending lung cancer drug which targets a specific genetic mutation recommended by NICE
Taking medicines such as painkillers over a prolonged period of time to relieve headaches can actually make symptoms worse, according to latest guidelines from NICE.
Patients should be more involved in decisions about their care, says NICE
A new collaborative, made up of the UK’s leading health care organisations including NICE, has set out plans that will help get patients more involved in decisions about their care.
Patients with blood clots should be treated within 4 hours, says NICE
People who present to hospital with blood clots in the legs or lungs should be offered treatment within 4 hours and have their investigative tests including scans within 24 hours, according to latest guidelines.